Loading
HKSEHealthcareBiotechnology
Latest quote
HK$1.33
−HK$0.02 · -1.48%
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
Latest quote
HK$1.33
−HK$0.02 · -1.48%
Regular session · HKT · Market data may be delayed.
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
Day range
Current HK$1.33
52-week range
Current HK$1.33
Regular session · HKT · Market data may be delayed.
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
Day range
Current HK$1.33
52-week range
Current HK$1.33
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.73B CNY | 1.99B CNY | 2.16B CNY | 2.38B CNY | 2.1B CNY |
| Cost of goods sold | 1.07B CNY | 1.3B CNY | 1.42B CNY | 1.56B CNY | 1.45B CNY |
| Gross profit | 655.56M CNY | 687.4M CNY | 738.43M CNY | 815.68M CNY | 650.98M CNY |
| Research and development | 100.46M CNY | 87.99M CNY | 127.97M CNY | 135.84M CNY | 92.38M CNY |
| Selling, general, and administrative | 361.86M CNY | 364.12M CNY | 409.66M CNY | 404.45M CNY | 321.7M CNY |
| Operating expenses | 462.31M CNY | 457.73M CNY | 545.75M CNY | 546.33M CNY | 414.08M CNY |
| Interest income | 16.48M CNY | 20.54M CNY | 27.38M CNY | 21.61M CNY | 26.58M CNY |
| Interest expense | 36.55M CNY | 53.89M CNY | 176.58M CNY | 184.67M CNY | 183.11M CNY |
| Depreciation and amortization | 192.13M CNY | 198.33M CNY | 198.33M CNY | 170.37M CNY | 133.04M CNY |
| Operating income | 193.25M CNY | 229.67M CNY | 192.68M CNY | 269.35M CNY | 236.9M CNY |
| Net income | 219.76M CNY | 167.29M CNY | −116.11M CNY | −528.48M CNY | 287.55M CNY |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 16, 2021 | HK$0.01Special | Jun 17, 2021 | Jul 9, 2021 |
Dividend | Sep 11, 2020 | HK$0.017Quarterly | Sep 14, 2020 | Oct 6, 2020 |
Dividend | Jun 15, 2020 | HK$0.015Quarterly | Jun 16, 2020 | Jul 10, 2020 |
Dividend | Sep 9, 2019 | HK$0.005Special | Sep 10, 2019 | Sep 30, 2019 |
Ex-dividend Jun 16, 2021
HK$0.01
Special
Record Jun 17, 2021 · Payment Jul 9, 2021
Ex-dividend Sep 11, 2020
HK$0.017
Quarterly
Record Sep 14, 2020 · Payment Oct 6, 2020
Ex-dividend Jun 15, 2020
HK$0.015
Quarterly
Record Jun 16, 2020 · Payment Jul 10, 2020
Ex-dividend Sep 9, 2019
HK$0.005
Special
Record Sep 10, 2019 · Payment Sep 30, 2019
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Emerging Markets ETFSPEM573.23K0.00%18.03B USD0.07%$52.2523-1.35%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM359.47K0.00%9.8B USD0.39%$40.16-1.87%
Avantis Emerging Markets Equity ETFAVEM316.32K—28.93B USD0.33%$94.365-1.74%
Dimensional World ex U.S. Core Equity 2 ETFDFAX169.49K0.00%12.76B USD0.28%$37.81-1.05%
Dimensional - Emerging Core Equity Market ETFDFAE168.54K0.00%10.34B USD0.29%$39.745-1.91%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX111.52K0.02%689.05M USD0.65%$72.5701-1.39%
Dimensional - Emerging Markets Value ETFDFEV50.01K0.00%2.23B USD0.46%$42.855-1.78%
Avantis Emerging Markets Small Cap Equity ETFAVEE28.76K0.02%139.23M USD0.42%$68.76-1.28%State Street SPDR Portfolio Emerging Markets ETFSPEMDimensional - Emerging Markets Core Equity 2 ETFDFEMAvantis Emerging Markets Equity ETFAVEMDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Core Equity Market ETFDFAEState Street SPDR S&P Emerging Markets Small Cap ETFEWXDimensional - Emerging Markets Value ETFDFEVAvantis Emerging Markets Small Cap Equity ETFAVEEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
